This tag is associated with 3 posts

Opdivo® (nivolumab): Bristol-Myers Squibb’s Immunotherapy for Melanoma and Lung Cancer

In my inaugural blog post, I mentioned that I was going to break down each of the top 11 blockbuster drugs of 2015 as predicted by Thomson Reuters. As promised, I will start with number one on the list – Opdivo® (nivolumab), which was first approved as second line treatment of melanoma in December of 2014. Background … Continue reading

Antibiotic Resistance: An Emerging Threat

One of my most vivid recollections from residency training is that of a patient we had in the ICU who was gravely ill from an infection. We treated her infection as we usually do in these situations – supportive care and antibiotics. What was so unusual about her case that I still remember it to … Continue reading

11 Blockbuster Drugs for 2015 – What Are They and Who Is Making Them?

I’ve been reading a lot about this Thomson Reuters analysis about this year’s predicted blockbuster drugs (i.e., drugs predicted to make over $1 billion in US dollars). Their track record is pretty solid given they predicted big things for Gilead Sciences’ oral drug Sovaldi (sofosbuvir)/Harvoni (sofosbuvir plus ledipasvir) for hepatitis C viral infection, GlaxoSmithKline/Theravance’s Anoro Ellipta (umeclidinium … Continue reading